LINC00165

Across TCGA pan-cancer cohorts, LINC00165 RNA is linked to patient survival in 25 of 34 cancer types, making it the most broadly survival-associated LINC00165 data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher LINC00165 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated LINC00165 expression acts as an unfavorable survival marker, although some lineages such as SKCM and COAD show a favorable association.

LIHC, LUSC, and THYM are the cancer types where LINC00165 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Tertile	All	0.582	0.809	<.001	51	view →
LUSC	DFS	Tertile	III,IV	0.192	0.442	.002	46	view →
THYM	DFS	Tertile	III,IV	0.343	0.907	<.001	45	view →
DLBC	OS	Tertile	II,III,IV	0.430	0.895	.001	45	view →
LGG	OS	Median	All	0.358	0.500	<.001	41	view →
BRCA	DFS	Median	IV	0.297	0.793	<.001	36	view →
LUAD	DFS	Tertile	IV	0.495	0.898	.001	30	view →
PAAD	OS	Quartile	All	0.460	0.666	.002	26	view →
THCA	DFS	Tertile	II,III,IV	0.596	0.894	.002	13	view →
MESO	OS	Median	All	0.309	0.453	.025	12	view →
BLCA	DFS	Tertile	IV	0.256	0.604	.006	12	view →
STAD	DFS	Tertile	III,IV	0.443	0.672	.013	12	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 25 lineages.

LINC00165–LIHC (OS)

Open the LIHC breakdown →